HEAT BIOLOGICS DL-,0002 Forum: Community User: Newcomer35

Mal kurz 1000000 Aktien vergessen.🙈

https://ir.heatbio.com/sec-filings-email/content/0001553350-19-000432/htbx_10k.htm

Hoffe auch auf News

Man hoffentlich passiert bald was mit den chinitzen !🙏🏼

USA handelt heute

Danke 😀

Ja auch Danke von meinerseits....👍

Danke für die Infos.

https://ir.heatbio.com/sec-filings-email/content/0001553350-19-000414/htbx_8k.htm

👍🏻Perfekt. Ich glaube es geht bald wieder nach Norden.

DURHAM, NC / ACCESSWIRE / April 18, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces that Jeff Wolf, Chief Executive Officer, is scheduled to present at the ThinkEquity Conference on Thursday, May 2nd, at 8:00 AM Eastern Time, which is being held at The Mandarin Oriental Hotel in New York City. Additional information on the conference is available at, https://www.think-equity.com/thinkequity-conference. About Heat Biologics, Inc. Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform ("TCAP") produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACTtechnology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. For more information, please visit www.heatbio.com. Media and Investor Relations Contact David Waldman +1 919 289 4017 investorrelations@heatbio.com SOURCE: Heat Biologics, Inc. Released April 18, 2019

Auch grad gelesen. Verlängerung der Unterstützung bis November. Sehr gut 👍

https://ir.heatbio.com/sec-filings-email/content/0001553350-19-000413/htbx_8k.htm

Fragt man sich warum vor 2 Tagen hier 6xxxxx Stk gehandelt wurden 🤔

Aktien.check

*** ist Schrott. Jeden Tag hauen die allgemeine Phrasen zu allen möglichen Aktien raus.